JDJaime Sou Rosa Duque

Jaime Sou Rosa Duque

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jaime Sou Rosa Duque has a total of 667 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MHC-II deficiency in a large Algerian cohort: Clinical, immunological, and genetic characterization

    by Lydia Lamara Mahammed, Brahim Belaid, Koon-Wing Chan, Aida Mohand-Oussaid, Ouardia Drali, Abdelhak Dehimi, Daniel Leung, Lilya Meriem Berkani, Hassiba Sakhri, Asmaa Abed, et al.

    MHC class II (MHC-II) deficiency is a rare inborn error of immunity caused by defects in transcriptional regulators of MHC-II expression. In this study, we characterized the clinical, immunological, and molecular features of 107 patients from 98 unrelated Algerian families. Median ages at symptom onset and diagnosis were 5 and 14 mo, respectively, with pneumonia (82%) and chronic diarrhea (73%) predominating. CD4+ T cell lymphopenia occurred in 87.6% and naïve CD4+ T cell depletion in 86.0%. Among 99 genetically characterized patients, variants were identified exclusively in RFXANK (77.8%) and RFXAP (22.2%), including two predominant mutations (RFXANK c.338-25_338del and RFXAP c.368del) and four novel variants. Exploratory comparisons suggested a more severe phenotype in patients carrying RFXAP c.368del than in those carrying RFXANK c.338-25_338del. Five of seven transplanted patients survived versus 33.3% of non-transplanted patients. As the largest MHC-II deficiency cohort reported to date, this study substantially expands current knowledge of the disease and supports targeted genetic diagnosis in North African populations.

  • Open Access

    The genetic landscape of RAG deficiency: Novel and founder variants in a large Algerian cohort

    by Brahim Belaid, Koon-Wing Chan, Jennifer Stoddard, Julie Niemela, Heather Kenney, Adriana A. De Jesus, Daniel Leung, Jing Yang, Xing Tian Yang, Abdelhak Dehimi, et al.

    RAG1/RAG2 deficiency causes diverse SCID phenotypes, but large, systematically characterized cohorts from North Africa remain lacking. We retrospectively characterized 128 confirmed RAG1/RAG2-deficient patients diagnosed over 14 years in Algeria, classified per PIDTC 2022 criteria. Consanguinity was high (70.3%), with RAG2 (57.0%) outnumbering RAG1 (43.0%), a reversal of patterns reported elsewhere. Classical SCID (61.0%) and Omenn syndrome (23.4%) predominated. Two candidate founder variants (RAG1 c.519del, RAG2 c.104G>T) accounted for 76.6% of genotypes, yet identical c.519del genotypes produced three discordant phenotypes. Four novel variants and four digenic/oligogenic cases broadened the molecular spectrum. Despite a short diagnostic delay, mortality was 89.1%, driven primarily by near-absent HSCT access (2.3%). This study expands the molecular and clinical spectrum of RAG deficiency in an underrepresented population, revealing a reversed RAG1/RAG2 ratio and phenotypic heterogeneity despite shared founder genotypes. These findings prioritize functional validation of uncertain-significance variants and underscore the need for NBS and expanded transplant access to translate diagnosis into survival.

  • Open Access

    Variability in the TLR3 type I interferon pathway is predictive of RNA vaccine responses

    by Wilson W. Ng, Jamie Sugrue, Jaime S. Rosa Duque, Vincent Rouilly, Vincent Bondet, Chloe Albert, Florian Dubois, Marie Robert, Daniel Leung, Peter Chung, et al.

    Biological predictors of variable vaccine responses are lacking. We hypothesized that variability in prevaccine innate immune responses, specifically for type I interferons (IFN-I), is predictive of postvaccine antigen-specific responses. To test this, we assessed prevaccine immune responses at protein and transcriptomic levels following whole blood stimulation with Toll-like receptor (TLR) viral agonists in healthy adolescents and adults. Four weeks after the second vaccine dose, with either the BNT162b2 mRNA or CoronaVac inactivated virus vaccine, we assessed antigen-specific T cell cytokine responses and plasma antibody levels. BNT162b2 vaccinees had increased production of the antigen-specific T cell cytokines interleukin-2 (IL-2), interferon-γ, and IL-21 after severe acute respiratory syndrome coronavirus 2 spike stimulation, as well as increased antibody levels and serum pseudo-neutralization compared with CoronaVac recipients. In direct support of our hypothesis, we find that prevaccine poly(I:C) (polyinosine-polycytidylic acid; TLR3 viral agonist) IFN-I responses were significantly associated with the postvaccine T cell cytokine responses. In an independent cohort of 990 healthy donors, we confirmed the significant association between poly(I:C)-induced IFN-α and spike-induced cytokines in mRNA vaccine recipients. We further confirmed this specific association in a cohort of healthy Europeans and identified a common genetic polymorphism in TLR3 that affects IFN-I induction and subsequent vaccine-specific T cell responses. This study shows that preexisting innate immune variability can predict the effectiveness of vaccine responses and identifies pathways relevant to mRNA vaccination. Targeting the specific innate immune pathway relevant for a vaccine may provide a new approach for tailoring vaccines to different populations.


  • Open Access

    Four doses of coronavirus disease 2019 vaccination for patients with inborn errors of immunity compared to 3 doses for healthy individuals

    by Jeffery C.H. Chan, Samuel M.S. Cheng, Daniel Leung, Xiwei Wang, Manni Wang, Yin Celeste Cheuk, Cyrus Ho, Leo C.H. Tsang, Tsz Chun Kwan, Amos M.T. Lee, et al.

  • Open Access

    SDrecall: a sensitive approach for variant detection in segmental duplications

    by Xing Tian Yang, Chun Hing She, CaiCai Zhang, Daniel Leung, Jing Yang, Koon-Wing Chan, Jaime S. Rosa Duque, Yu Lung Lau, Wanling Yang

    Variant calling in segmental duplications is challenging for short-read sequencing because of ambiguous read origins. We present SDrecall, a method for sen


  • Open Access

    Achieving and sustaining measles elimination in Hong Kong, from 1967 to 2024: lessons to be learnt

    by Jeffery Ching Ho Chan, Jaime S Rosa Duque, David N Durrheim, Thomas Tsang, Yu Lung Lau

    Following the development and roll-out of the measles vaccine in 1954, measles incidence dropped to low levels in areas where measles vaccines with high coverage were introduced. The Measles and Rubella Strategic Framework 2021–2030 developed by the Measles & Rubella Initiative aims to eliminate measles globally by 2030. However, there has been a resurgence of measles cases after the COVID-19 pandemic in many countries, including some in the Western Pacific Region. This review describes the journey from 1967, when Hong Kong introduced a single-dose regimen, to 2024 when Hong Kong had been experiencing an increase in imported measles cases despite being verified to have achieved measles elimination in 2016. Hong Kong’s experience in maintaining high vaccination coverage and comprehensive surveillance may provide an exemplary framework for other countries in the Western Pacific Region.


  • Open Access

    Healthcare resources for inborn errors of immunity in the Asia-Pacific region

    by Motoi Yamashita, Yunfei An, Dharmagat Bhattarai, Vicky Wee Eng-Binas, Suravat Homvises, Intan Hakimah Ismail, Mahnaz Jamee, Dae Chul Jeong, Peter McNaughton, Dina Muktiarti, et al.

    Surveys of healthcare infrastructure for inborn errors of immunity across the Asia-Pacific region reveal significant diagnostic and therapeutic disparities. These data provide a framework for regional policy improvements and highlight the need for equitable resource distribution.


  • Open Access

    Fish Allergenicity Ladder and Parvalbumin Epitopes for Predicting Clinical Cross‐Reactivity and Reintroduction in Chinese Population

    by Christine Y. Y. Wai, Nicki Y. H. Leung, Agnes S. Y. Leung, Man Fung Tang, Åsa Marknell DeWitt, Jaime S. Rosa Duque, Gilbert T. Chua, Yat Sun Yau, Wai Hung Chan, Po Ki Ho, et al.

    Background: IgE‐mediated fish allergy has long been considered an umbrella term due to the high cross‐reactivity of parvalbumin, the major fish allergen. Yet, clinical tolerance to certain fish highlights allergenicity differences. In this study, we sought to construct a fish allergenicity ladder and identify fish parvalbumin epitopes to improve the diagnosis of fish allergy.Methods: Reported clinical history and the serum‐specific IgE (sIgE) responses of 200 Chinese subjects with suspected fish allergy were collected and analyzed, while the relative parvalbumin content in different fish was measured for the construction of a fish allergenicity ladder. Double‐blind placebo‐controlled food challenge (DBPCFC) and open challenge against salmon, grass carp, and grouper were performed in 58 selected patients for validation of the ladder. Epitope mapping was performed by peptide array against parvalbumins of salmon (both β‐1 and β‐2), cod, grouper, and grass carp with sera from fish allergic (n = 11), partial fish tolerant (n = 12), and complete fish tolerant (n = 5) patients diagnosed based on oral food challenge outcome.Results: The distribution pattern of reported history of fish allergy and tolerance, sIgE and molecular data, as well as their strong positive correlation led to the construction of a 3‐step fish allergenicity ladder comprising: step 1 of the least allergenic fishes (tuna, halibut, salmon and cod), steps 2 of moderately allergenic fishes (herring and grouper) to step 3 of highly allergenic fishes (catfish, grass carp and tilapia). Epitope mapping revealed one epitope from grouper parvalbumin (AA64‐78) for diagnosing general fish allergy and one epitopic region from salmon parvalbumin (AA19‐33) as a biomarker of specific fish tolerance. Only epitope‐specific IgE differentiated these patients but not sIgE to fish extract or parvalbumin.Conclusion: The fish ladder and epitopes discovery can precisely differentiate fish‐allergic and tolerant subjects and guide fish reintroduction by stepping up the ladder, which innovates fish allergy care in the next millennium.


  • Open Access

    Perioperative anaphylaxis in children and first successful cisatracurium desensitization

    by Sophie H. Y. Lai, Rowena S. M. Lee, Crystal K. Lam, Andrew K. H. Yik, Qin Ying Lim, Florence Choi, Donna M. Lynch, Kathleen A. Marquis, Kaiyue Zhang, Kai‐Ning Cheong, et al.

    Background: Perioperative anaphylaxis (PA) is a rare life‐threatening complication of anesthesia, with few descriptions of its diagnosis and outcomes in the pediatric population. Many agents can be potential culprits, and drug provocation testing (DPT) to confirm the diagnosis is limited by the nature of anesthetic drugs. PA diagnosis and culprit identification remain a challenge. For patients with limited drug options, desensitization has not been reported. This study evaluated the results of skin and laboratory testing for pediatric patients with PA and provides the protocol and outcome of the first desensitization to cisatracurium, a neuromuscular blocking agent (NMBA).Methods: Patients ≤18 years old with PA from 2019 to 2024 were included, and medical records were retrospectively reviewed, which comprised serum tryptase levels, results of skin testing (ST), basophil activation testing (BAT), and outcomes.Results: Eleven patients were included. Tryptase was elevated in seven of 10 (70%) tested patients. ST yielded positive results for nine of 10 (90%), and two of 11 (18.2%) had positive BAT.Results: A culprit agent was identified in 10 of 11 (91%). The most common drugs were NMBAs (70%) and beta‐lactam antibiotics (20%). One patient with a positive DPT to NMBAs and limited alternatives was successfully desensitized to cisatracurium with a 3‐bag, 12‐step protocol.Conclusion: The most common drug culprits of PA in children were NMBAs and were identified by ST. Tryptase correlated with PA. BAT served as adjunctive diagnostic tests. Desensitization to cisatracurium was possible.


  • Open Access

    Humoral and cellular immunogenicity of a fourth dose BNT162b2 in children with chronic kidney diseases

    by Jeffery C H Chan, Eugene Yu-Hin Chan, Samuel M S Cheng, Daniel Leung, Fanny Tsz-Wai Ho, Pak-Chiu Tong, Wai-Ming Lai, Matthew H L Lee, Stella Chim, Leo C H Tsang, et al.

    Background: Children with chronic kidney disease (CKD) are at risk of severe complications after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and are recommended to receive vaccine boosters. Although coronavirus disease 2019 (COVID-19) boosters are effective in providing immune responses among healthy children, data on the use of a fourth dose among children with CKD are limited. Methods: We prospectively investigated the immunogenicity and safety of a fourth dose of BNT162b2 in children with CKD. Dosages were 0.1 mL and 0.3 mL for children aged 5–11 years and 11–18 years, respectively. Humoral and cellular immunogenicity was assessed at pre-dose 4, and at 1 and 6 months post-dose 4. Results: Twenty-one children, with a median age of 14.0 years, were included for evaluation. A fourth dose of BNT162b2 elicited significant increases in humoral spike receptor–binding domain immunoglobulin G levels and T-cell responses. Antibody responses were significantly lower among kidney transplant recipients or children receiving calcineurin inhibitors than other CKD children at 1 month post-dose 4. Breakthrough COVID-19 occurred in three children after the fourth dose, and one was hospitalized. One child developed mild gross hematuria 1 day after the fourth dose, which spontaneously resolved. The overall safety profile was acceptable. Conclusions: A fourth dose of BNT162b2 was immunogenic and safe in children with CKD.